Cyclophosphamide, Methotrexate, and 5-Fluorouracil (CMF)-Induced Ocular Toxicity

References

• Wood W C, Weiss R B, Tormey D C, et al. A randomized trial of CMF versus CMFVP as adjuvant chemotherapy in women with node-positive stage n breast cancer: A CALGB study. World J Surg 1985; 9: 714–718
   PubMed Web of Science ®Google Scholar
• Taylor S G, Kalish L A, Olson J E, et al. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: Three-year results of an Eastern Cooperative Oncology Group Study. J Clin Oncol 1985; 3: 144–154
   PubMed Web of Science ®Google Scholar
• Tormey D C, Weinberg V E, Holland J F, et al. A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer. J Clin Oncol 1983; 3: 138–145
   Google Scholar
• Tancini G, Bonadonna G, Valagussa P, et al. Adjuvant CMF in breast cancer: Comparative 5-year result of 12 versus 6 cycles. J Clin Oncol 1983; 1: 2–10
   PubMed Web of Science ®Google Scholar
• Brincker H, Mouridsen H T, Andersen K W. Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer. Breast Cancer Res Treat 1983; 3: 91–95
   PubMed Web of Science ®Google Scholar
• Ludwig Breast Cancer Study Group. Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer. J Clin Oncol 1986; 3: 1059–1067
   Web of Science ®Google Scholar
• Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: 405–410
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Valagussa P. Current status of adjuvant chemotherapy for breast cancer. Semin Oncol 1987; 15: 8–22
   Google Scholar
• Stetson P L, Shukla U A, Ensminger W D. Sensitive high-performance liquid chromatographic method for the determination of 5-fluorouracil in plasma. J Chromatogr 1985; 344: 385–390
   PubMed Web of Science ®Google Scholar
• Love R R, Leventhal H, Easterling D V, et al. Side effects of emotional distress during cancer chemotherapy. Cancer 1989; 63: 604–612
   PubMed Web of Science ®Google Scholar
• Mahmoud Y, Sayed E, Sadeé W. The fluoropyrimidines. Pharmaceutics of Anticancer Agents in Humans, M M Ames, G Powis, J S Kovach. Flsevier Science Publishers B. V., Amsterdam 1983; 209–227
   Google Scholar
• Cohen J M. Cromolyn for chemotherapy conjunctivitis (Letter to the Editor). J Clin Oncol 1985; 3: 1690
   PubMed Web of Science ®Google Scholar
• Griffin J D, Garnick M B. Eye toxicity of cancer chemotherapy: A review of the literature. Cancer 1981; 48: 1539–1549
   PubMed Web of Science ®Google Scholar
• Vizel M, Oster M W. Ocular side effects of cancer chemotherapy. Cancer 1982; 49: 1999–2002
   PubMed Web of Science ®Google Scholar
• Oster M W. Ocular side effects of cancer chemotherapy. Toxicity of Chemotherapy, M C Perry, J W Yarbro. Grune and Stratton, Orlando, FL 1984
   Google Scholar
• Fraunfelder F T, Meyer S M. Ocular toxicity of antineoplastic agents. Ophthalmology 1983; 90: 1–3
   PubMed Web of Science ®Google Scholar
• Hansen H H, Selawry O S, Holland J F, McCall C B. The variability of individual tolerance to methotrexate in cancer patients. Br J Cancer 1971; 25: 298–305
   PubMed Web of Science ®Google Scholar
• Doroshow J H, Locker G Y, Gaasterland D E, et al. Ocular irritation from high-dose methotrexate therapy: Pharmacokinetics of drug in the tear film. Cancer 1981; 48: 2158–2162
   PubMed Web of Science ®Google Scholar
• Hussain M I. Ocular irritation from low-dose methotrexate (letter). Cancer 1982; 50: 605
   PubMed Web of Science ®Google Scholar
• Christophidis N, Vajda F JE, Lucas I, Louis W J. Ocular side effects with 5-fluorouracil. Aust NZ J Med 1979; 9: 143–144
   PubMedGoogle Scholar
• Fraunfelder F T. Interim report: National Registry of possible drug induced ocular side effects. Ophthalmology 1980; 87: 87–90
   PubMed Web of Science ®Google Scholar
• Dillaha C J, Jansen G R, Honeycutt W M, Bradford A C. Selective cytotoxic effect of topical 5-fluorouracil. Arch Dermatol 1963; 88: 247–256
   PubMed Web of Science ®Google Scholar
• Lee D A, Hersh P, Kersten D, Melamed S. Complications of sub-conjunctival 5-fluorouracil following glaucoma filtering surgery. Ophthal Surg 1987; 18: 187–190
   PubMedGoogle Scholar
• Bruckner H W, Cohen J. MTX/5-FU trials in gastrointestinal and other cancers. Semin Oncol 1983; 10: 32–39
   PubMed Web of Science ®Google Scholar
• deBruijn E A, Driessen O, Leeflang P, et al. Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model. Cancer Treat Rep 1987; 71: 1267–1269
   PubMedGoogle Scholar
• Moran R G. Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase. Cancer 1989; 63: 1008–1012
   PubMed Web of Science ®Google Scholar
• Duke-Elder S. System of Ophthalmology. CV Mosby, St. Louis 1965; Vol. 8: 601–614, part 2
   Google Scholar
• Shapiro M S, Thoft R A, Friend J, et al. 5-Fluorouracil toxicity to the ocular surface epithelium. Invest Opthalmol Vis Sci 1985; 26: 580–583
   PubMed Web of Science ®Google Scholar
• Caravella L P, Burns J A, Zangmeister M. Punctal-canalicular stenosis related to systemic fluorouracil therapy. Arch Ophthalmol 1981; 99: 284–286
   PubMed Web of Science ®Google Scholar
• Straus D J, Mausolf F A, Ellerby R A, et al. Cicatrical ectropion secondary to 5-fluorouracil therapy. Med Pediatr Oncol 1977; 3: 15–19
   PubMedGoogle Scholar
• Haidak D J, Hurwitz B S, Yeung K Y. Tear duct fibrosis (dacryostenosis) due to 5-fluorouracil. Ann Intern Med 1978; 88: 657
   PubMed Web of Science ®Google Scholar
• Insler M S, Helm C J. Ankyloblepharon associated with systemic 5-fluorouracil treatment. Ann Ophthalmol 1987; 19: 374–375
   PubMed Web of Science ®Google Scholar
• Foster C S, Duncan J. Randomized clinical trial of topically administered cromolyn sodium for vernal keratoconjunctivitis. Am J Ophthalmol 1980; 909: 175–181
   Google Scholar
• Dean J C, Salmon S E, Griffith K S. Prevention of doxorubicin-induced hair loss with scalp hypothermia. N Engl Med 1979; 301: 1427–1429
   PubMed Web of Science ®Google Scholar
• Lass J H, Lazarus H M, Reed M D, et al. Topical corticosteroid therapy for corneal toxicity from systemically administered cytarabine. Am J Ophthalmol 1982; 94: 617–621
   PubMed Web of Science ®Google Scholar